Global

Artificial Intelligence Company Led by Demis Hassabis Secures Five Billion Dollars in Funding

Originally reported by CNBC Global as: Demis Hassabis’ AI company raises $5 billion, months after he left as Google DeepMind CEO

17 Nov 2026, 7:28 pm IST · Xecute.finance News DeskArchive edition

The crisp read

Isomorphic Labs, founded by Demis Hassabis, raised five billion dollars in new funding just months after he departed from his role as Google DeepMind Chief Executive Officer. The enterprise focuses on developing novel medicines using advanced artificial intelligence technologies.

Deep dive – the full story

Isomorphic Labs, an artificial intelligence company focused on drug discovery, has secured five billion dollars in a major funding round. This capital raise occurred just months after founder Demis Hassabis stepped down from his position as Chief Executive Officer of Google DeepMind to concentrate on the venture. Venture funding in artificial intelligence-driven biotechnology supports intensive computational research aimed at identifying and developing novel therapeutic molecules.

Applying machine learning models to biological data accelerates preclinical drug discovery pipelines by simulating molecular interactions far faster than traditional laboratory experimentation methods. Technology investors and pharmaceutical analysts should monitor how large-scale capital deployments influence research breakthroughs and commercial partnerships in the life sciences sector. Stakeholders must evaluate competitive dynamics between independent artificial intelligence startups and established technology conglomerates.

Bottom line: substantial venture backing in computational biology signals accelerated innovation and rising commercial stakes in AI-driven healthcare solutions.

Source: cnbc.com

This is news/educational content, not investment advice. Xecute.finance is not SEBI-registered. Consult a qualified professional before acting.

More from the Xecute news desk

Reading the archive edition.

This story has retired from the live feed - the full text stays here permanently. The live app adds the newest desk, Ask Xecute, deadline trackers and the daily quiz.

Open this story in the Xecute app →